EarningsQ2 2026 Earnings Report
DE:IDDA Q2 2026 EPS Results
Actual EPS-€0.21
Consensus EPS-€0.16
Beat/MissMissed by -€0.05
One Year Ago EPS-€0.26
DE:IDDA Q2 2026 Revenue Results
Actual Revenue€3.19M
Expected Revenue€8.07M
Beat/MissMissed by -€4.87M
YoY Revenue Growth+99.10%
Earnings Announcement Details
QuarterQ2 2026
Date09/17/2026
TimeBefore Open
Conference CallThursday, September 17, 2026
DE:IDDA Upcoming Earnings
Innate Pharma's next earnings date is estimated for March 25, 2027, based on past reporting schedules.
Q2 2026 Earnings Call Audio
DE:IDDA Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a strongly positive outlook, with the lacutamab partnership closing, Phase 3 initiation, preliminary IPH4.5 thousand objective responses and favorable safety observations, completed monalizumab enrollment, multiple upcoming catalysts, and a cash runway expected through the end of the first quarter of 2028. The main qualifications were that IPH4.5 thousand data remain early, the post-enfortumab vedotin urothelial cancer setting lacks an established second-line standard, and broader development could require additional funding.Company Guidance
Lacutamab Partnership Closed and Phase 3 Initiated
The strategic partnership with Sobi to advance lacutamab in T-cell lymphoma has closed and become effective. The TELLOMAK-3 confirmatory Phase 3 study has been initiated, with the first patient expected in the first quarter of 2027.
Planned Lacutamab Accelerated Approval Filing
Innate plans to file for accelerated approval in Sezary Syndrome in the second half of 2027 based on the existing Phase 2 TELLOMAK data once TELLOMAK-3 is underway. The study includes a confirmatory cohort in Sezary Syndrome and a registrational cohort in mycosis fungoides.
Lacutamab Regulatory Designations
Lacutamab has received FDA breakthrough therapy designation and fast track designation for relapsed or refractory Sezary Syndrome, PRIME designation from the EMA, and orphan drug status in both the United States and Europe.
Lacutamab Partnership Economics
The Sobi agreement includes a $75 million upfront payment, up to $40 million in near-term milestones connected to Sezary Syndrome, and up to an additional $465 million related to Sobi's option to obtain full development rights and future regulatory and commercial milestones. The agreement also includes tiered double-digit royalties on future net sales.
IPH4.5 thousand Phase 1 Progress and Preliminary Responses
IPH4.5 thousand completed Phase 1 dose escalation and cohort enrichment enrollment in July. Preliminary antitumor activity, including objective responses, has been observed in heavily pretreated patients with urothelial cancer following prior enfortumab vedotin treatment, as well as in non-small cell lung cancer and head and neck cancer.
Favorable IPH4.5 thousand Safety Profile to Date
The safety profile observed to date for IPH4.5 thousand has been described as favorable, with limited hematological toxicity. Management attributed the profile in part to the stability of the proprietary linker and limited release of the free payload observed in preclinical models and appearing to translate into the human situation.
IPH4.5 thousand Clinical Data Presentation Planned
Initial Phase 1 dose escalation data for IPH4.5 thousand are scheduled to be presented at the EORTC-NCI-AACR Symposium on November 18, 2026, in Barcelona. Management expects response data and relevant, informative safety data from 11 different indications and 76 patients, which will inform next steps.
IPH4.5 thousand Cohort Enrollment Progress
The company said it is broadly tracking in line with expectations across expansion cohorts, with approximately 15 patients enrolled in each of the post-enfortumab vedotin urothelial cancer and head and neck cancer cohorts, and somewhat lower enrollment in the non-small cell lung cancer cohort.
IPH4.5 thousand Differentiated ADC Design
IPH4.5 thousand combines an exatecan topoisomerase-I payload, a proprietary stable linker, and a high-affinity Nectin-4 antibody that binds a non-overlapping epitope compared with enfortumab vedotin. The company said these features are intended to address limitations of first-generation Nectin-4 ADCs.
Monalizumab Phase 3 Enrollment Completed
Enrollment in the PACIFIC-9 randomized Phase 3 study of monalizumab in unresectable Stage III non-small cell lung cancer has been completed. The study enrolled 1.05 thousand patients, and the Phase 3 readout remains expected in the second half of 2026.
Monalizumab Partnership Economics
Under the monalizumab partnership with AstraZeneca, Innate has received $450 million to date. The agreement includes up to $825 million in additional potential milestones, double-digit royalties outside Europe, and 50% profit sharing in Europe.
Next-Generation ADC Pipeline Expansion
Beyond IPH4.5 thousand, Innate is using its internal capabilities and technology to build a broad portfolio of differentiated ADC candidates. The company described three approaches: dual-targeted bispecific ADCs, bispecific ADCs with enhanced internalization, and dual-payload ADCs using complementary mechanisms of action.
Strengthened Financial Position
As of June 30, 2026, cash equivalents and financial assets amounted to €21.4 million, excluding the $75 million Sobi upfront payment, equivalent to €65 million, and proceeds from the equity offering. The €30 million offering generated €30 million in gross proceeds and €28 million in expected net proceeds.
Cash Runway Extended Through First Quarter 2028
Together, the Sobi upfront payment and equity financing are expected to extend the projected cash runway through the end of the first quarter of 2028. Proceeds are intended for continued clinical development of IPH4.5 thousand, advancement of the preclinical ADC portfolio, and general corporate purposes.
Funding Available for Initial IPH4.5 thousand Next Steps
Management said the recent €30 million equity raise positions the company to progress seamlessly into the initial next steps for IPH4.5 thousand, including dose optimization.
Potential Lacutamab Pricing Range
Pricing research conducted in the United States by ZS Associates indicated that lacutamab could be priced between $500 thousand and $650 thousand per patient per annum. Management said the pricing would be supported by clinical data and potential NCCN listing.
Three Near-Term Portfolio Catalysts
Management highlighted three important near-term catalysts: TELLOMAK-3 progress for lacutamab with first patient planned for the first quarter of 2027, initial Phase 1 dose escalation data for IPH4.5 thousand on November 18, 2026, and the PACIFIC-9 Phase 3 readout for monalizumab expected in the second half of 2026.
DE:IDDA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed